Health Condition 1: C795- Secondary malignant neoplasm of bone and bone marrow
Conditions
Interventions
Intervention1: VBDNSM01 (Denosumab): Each single vial contains 120 mg of Denosumab in 1.7 mL of solution (70 mg/mL). Frequency: every 4 weeks
Duration of treatment: 24 weeks (a total of six doses)
Control Intervention1: Xgeva (Denosumab): Each single vial contains 120 mg of Denosumab in 1.7 mL of solution (70 mg/mL). Frequency: every 4 week
Duration of treatment: 24 weeks (a total of six doses)
Sponsors
Virchow Biotech Private Limited
Eligibility
Inclusion criteria
Inclusion criteria: 1.Male or female with � 18 to � 75 years. 2.Histological or Cytological confirmation of Breast adenocarcinoma or Prostate cancer or Non-small cell lung cancer. 3.Radiographic evidence of atleast 1 bone metastasis (Confirmed by X-ray, computed tomography, magnetic resonance imaging or bone scan). 4.Eastern Cooperative Oncology Group performance status �2. 5.Willing to provide written informed consent and comply with protocol requirements. 6.Able to communicate well with the investigator, to understand and comply with the requirements of the study. 7.Patients of child-bearing potential must agree to use acceptable methods of contraception (as per investigator discretion) during the study. Female patients of child bearing potential must agree to use contraceptive methods for atleast 5 months after the last dose of the drug.
Exclusion criteria
Exclusion criteria: 1.History of hypersensitivity to denosumab or prior use of denosumab. 2.Any of the following oral/dental conditions: Prior history or current evidence of osteomyelitis or osteonecrosis of the jaw. Active dental or jaw condition which requires oral surgery. Planned invasive dental procedure. Non-healed dental or oral surgery. 3.Administration of intravenous (IV) bisphosphonates, fluoride, or strontium for osteoporosis within the last 1 year or oral bisphosphonates treatment for osteoporosis in last 3 months. 4.Currently enrolled in or has not yet completed at least 30 days (or 5 half-lives, whichever is longer) since ending earlier investigational device or drug trial(s), or patient is receiving another investigational agent(s). 5.Planned bone surgery or radiation to the bone. 6.Life expectancy less than 6 months. 7.Serum calcium levels ââ?°Â¤8 mg/dl. 8.Estimated creatinine clearance ââ?°Â¤30 ml/min. 9.Females with a positive pregnancy test at screening or lactating females. 10.Tested positive for HIV, HCV or HBsAg or known to be tested positive. 11.Un controlled hypertension (Blood pressure ââ?°Â¥ 140 by 90 mm of Hg). Patient on stable antihypertensive medication for more than 3 months with controlled hypertension will be eligible. 12.Any other significant medical condition which in the opinion of the investigator increases the safety risk if patient participate in the trial. 13.Clinically relevant ECG abnormality that affects the successful completion of patientââ?¬•s treatment in the trial as per investigator. 14.Recent history (within the past 1 year) of myocardial infarction or cerebral stroke or patients with NYHA III or IV heart failure. 15.History of drug or alcohol abuse within the 12 months prior to dosing. 16.Any of the following abnormal investigational values: a.General: Any laboratory abnormality which, in the opinion of the Investigator, would prevent the patient from safely completing the study or interfere with the interpretation of the study results. b.Liver transaminases: i.AST or SGOT ââ?°Â¥2.0 x upper limits of normal ULN; ii.ALT or SGPT ââ?°Â¥2.0 x ULN; iii. Alkaline phosphatase and bilirubin ââ?°Â¥1.5 x ULN.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Proportion of patients having skeletal-related eventsTimepoint: 24 weeks | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. Proportion of patients having skeletal-related events at week 12;Timepoint: week 12;2. Time to first skeletal-related eventsTimepoint: 0-24 weeks;4. Mean decrease in urinary N-telopeptide adjusted for creatinine (uNTx/Cr) from baseline to week 4, 12, 20 and 24Timepoint: week 4, 12, 20 and 24 | — |
Countries
India
Contacts
Public ContactVishaly
Virchow Biotech Private Limited
Outcome results
None listed